Can a diabetes drug help dialysis patients manage fluid buildup?
NCT ID NCT05786443
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether empagliflozin, a diabetes medicine, is safe and helps control body fluid levels in 60 adults who are starting hemodialysis for end-stage kidney disease. Participants will take either empagliflozin or a placebo for 12 weeks. The goal is to see if the drug improves fluid balance and blood pressure without causing harm.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 021215, United States
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug work safely in patients with kidney failure?
- What does life feel like for children with a rare birth defect? a new study asks
- AI therapy coach aims to ease distress in seriously ill seniors
- A simple stretch during dialysis might soothe restless legs
- A regenerative graft could rethink dialysis access
- Pumpkin seed oil may fight inflammation in kidney patients — a trial puts it to the test